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Abstract Chitotriosidase (ChT) is a human chitinase
secreted by activated macrophages and its activity is used
in therapeutic monitoring of Gaucher disease (GD), the most
common lysosomal storage disease. About 6% of the
population is homozygous for a duplication of 24 bp in
exon 11 of the CHIT1 gene (dup24), which is the main
polymorphism that results in the absence of ChT. As ChT
enzyme activity can be used as a biomarker in GD, it is
important to know the CHIT1 genotype of each patient. In
this study, ChT activity and CHIT1 genotype were evaluated
in 33 GD type 1 patients under treatment in the state of
Minas Gerais, Brazil, and compared to healthy controls. As
expected, the enzyme activity was found to be higher in GD
type 1 patients than in healthy subjects. Four patients had no
ChT activity. Their genotype revealed three patients (9%)
homozygous for dup24 allele and one patient with two
polymorphisms in exon 11: G354R and a 4 bp deletion at
the exon-intron 11 boundary (g.16993_16996delGAGT), the
later described for the first time in literature. Two other
patients with lower ChT activity presented a polymorphism
in exon 4 (c.304G>A, p.G102S), without dup24 allele. In
conclusion, this study demonstrated that ChT activity can be
used for therapeutic monitoring in 82% of GD patients of the
state of Minas Gerais, Brazil.
Introduction
Gaucher disease (GD; MIM 230800), the most prevalent of
the sphingolipid storage disorders, is caused by a genetic
defect that leads to glucocerebrosidase (b-glucosidade)
deficiency (EC 3.2.1.45) and progressive accumulation of
its substrate, glucocerebroside, in cells of monocyte/
macrophage origin (Brady et al. 1965; Beutler and
Grabowski 1995). Most patients present progressive vis-
ceral enlargement and gradual replacement of the bone
marrow with lipid-laden macrophages, hematological
abnormalities, and structural skeletal changes. Progressive
neurologic deterioration develops in a minority (Beutler and
Grabowski 1995).
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Patients with GD type 1 are commonly treated by
enzyme replacement therapy (ERT) with imiglucerase, only
produced by Genzyme Corporation (Cambridge, MA, UK),
a high-cost treatment provided by the Brazilian Ministry of
Health. The parameter most frequently employed to
monitor effectiveness of this therapeutic intervention is
the activity of chitotriosidase (ChT) (Cox et al. 2000;
Hollak et al. 1994, 2001; Mistry and Abrahamov 1997), a
chitinase encoded by the chitotriosidase gene (CHIT1;
MIM 600031). The CHIT1 gene is currently known to
possess 13 exons with sizes ranging from 30 to 1055 bp
(NG_012867.1, National Center for Biotechnology
Information, 2012; http://www.ncbi.nlm.nih.gov/gene/
1118).
The enzyme is synthesized by activated macrophages
and is usually highly increased in serum from GD type 1
patients (Froissart 2006; Hollak et al. 1994). However,
monitoring therapeutic response by measuring plasma ChT
activity has a pitfall: the complete absence of enzymatic
activity in approximately 6% of individuals (Boot et al.
1998). This observation can be explained by the homo-
zygozity for a duplication of 24 bp in exon 11 of the CHIT1
gene (dup24, rs3831317) preventing formation of active
enzyme (Boot et al. 1998). However, dup24, the main
mutation described, is not the only one with implications
for diagnosis and therapeutic monitoring of patients. Some
polymorphisms, such as G102S (c.304G>A, p.G102S,
rs2297950), G354R (c.1060G>A, p.G354R, rs9943208),
and A442V (c.1325C>T, p.A442V, rs1065761) have been
associated with reduced ChT activity (Bussink et al. 2009;
Grace et al. 2007; Lee et al. 2007).
The relative scarceness of data regarding the incidence of
GD in Brazil, the evidence that, as a group, Brazilian patients
may have a more aggressive form of the disease (Sobreira
et al. 2007), and the high cost of ERT to the public health
budget prompted us to study the biochemical and molecular
ChT profiles in an effort to assess treatment efficacy. Indeed,
in 2007, about 500 patients with GD type 1 were treated in
Brazil with 177,280 bottles of ERT being purchased at a cost
of over US$ 125 million (Souza et al. 2010). The effective
dose of imiglucerase is individually adjusted according to the
clinical status and treatment response of the patient. The dose
ranges from 15 to 60 U/kg and is supplied every 2 weeks
(Martins et al. 2009). For this purpose we correlated the
measure of plasma ChT activity with CHIT1 genotypes of
GD type 1 patients from the Hospital das Clinicas of the
Universidade Federal de Minas Gerais (HC-UFMG), and
compared with healthy controls. Ultimately we reasoned that
such studies could be valuable for the monitoring of ERT
effectiveness and help physicians to devise the best treatment
protocol strategies which would represent a more adequate
use of treatment resources and improvement of therapy
results for patients. We found that 9% of the patients
analyzed (P1, P2, and P3) presented null or low ChT activity




Seventeen female and 16 male GD type 1 patients under
treatment (32 in ERT with imiglucerase and one in substrate
reduction therapy – SRT) at the reference center in HC-
UFMG participated of this study. The median age of the
patients was 27 years (range: 5–62 years) and the median
treatment time was 11 years (range: 1–14 years). All
patients had diagnosis confirmed by measurement of
glucocerebrosidase activity in leukocytes (Beutler and Kuhl
1970) or cultured fibroblasts (Beutler et al. 1971). The
control group consisted of 33 healthy volunteers of which
18 were females and 15 were males. The median age of the
control group was 24 years (range: 8–52 years).
Ethics
The study was approved by the Ethics in Research
Committee of Universidade Federal de Minas Gerais, under
the numbers ETIC 625/07 and ETIC 0414.0.203.000-09,
and informed consent was obtained from all participants.
CHIT1 Genotyping
Samples of 4 mL of peripheral blood were collected from
GD type 1 patients in tubes containing EDTA and
immediately subjected to DNA extraction according to the
method described by Miller and coworkers (1988). DNA
samples from 33 healthy controls were collected using
buccal swabs and extracted with the BuccalAmp™ DNA
Extraction Kit (Epicentre, Madison, WI, USA). The DNA
samples were stored at 20 C until molecular analysis.
Genotyping for dup24 in CHIT1 gene was performed by
PCR using specific primers (ChTF: AGCTATCTGAAG-
CAGAAG and ChTR: GGAGAAGCCGGCAAAGTC) as
previously described (Boot et al. 1998). The 20 mL reaction
contained 1x PCR Buffer (Sigma-Aldrich Co., St. Louis,
MO, USA), 0.2 mM dNTPs, 0.2 mM of each primer, 1.25
mM MgCl2, 0.5 U Taq polymerase (Sigma-Aldrich Co., St.
Louis, MO, USA), and 50 ng of DNA template. The DNA
was denatured at 95 C for 2 min, and amplification was
performed by 35 cycles at 95 C for 20 s, 56 C for 20
s and 72 C for 30 s. The amplified fragments were
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separated by electrophoresis on a 2% agarose gel and
visualized by ethidium bromide staining. Genotypes were
determined by the presence or absence of wild type (75 bp)
and/or mutant (99 bp) bands.
The three patients (P1, P2, and P3) who presented null or
low levels of ChT activity in spite of being homozygous or
heterozygous for the dup24 wild type allele were screened
for three polymorphisms in CHIT1 that correlate with
reduced ChT activity: G102S, G354R, and A442V (Bussink
et al. 2009; Grace et al. 2007; Lee et al. 2007). PCR
amplification of the regions containing the polymorphisms
G102S (exon 4), G354R (exon 11), and A442V (exon 13)
was performed using specific primers detailed in Table 1.
The 40 mL reaction contained 1x PCR Buffer (Sigma-
Aldrich Co., St. Louis, MO, USA), 1.5 mM dNTPs, 0.2 mM
of each primer, 2.5 mMMgCl2, 1 U Taq polymerase (Sigma-
Aldrich Co., St. Louis, MO, USA), and 100 ng of DNA
template. The DNA was denatured at 95 C for 2 min, and
amplification was performed by 35 cycles at 95 C for 20 s,
56 C for 20 s, and 72 C for 30 s. The amplified fragments
were separated by electrophoresis on a 2% agarose gel and
visualized by ethidium bromide staining.
Fragments were purified from the agarose gel using the
Promega Wizard® SV Gel and PCR Clean-up System kit
(Promega Corporation, Madison, WI, USA) as recommen-
ded by the manufacturer. The purified samples were
sequenced (forward and reverse direction) in the ABI 3130
Genetic Analyzer (Applied Biosystems Inc, Foster City, CA,
USA), using the BigDye Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems Inc, Foster City, CA, USA) as
recommended by the manufacturer. Sequences were ana-
lyzed and aligned to the reference sequence of CHIT1 gene
NG_012867.1 using the CodonCode Aligner software
(http://www.codoncode.com/aligner/).
To confirm heterozygosity for the G102S polymorphism in
patient P2, the fragment containing the possible alteration was
cloned. Cloning was performed on PCR®II-TOPO® plasmid
using the TOPO TA Cloning Kit (Invitrogen™ Life Tech-
nologies, Carlsbad, CA, USA) as recommended by the
manufacturer.
Plasma ChT Activity
Plasma was obtained by centrifugation from peripheral
venous blood collected in EDTA and stored at –20 C until
enzymatic analysis at the Laboratory of Inborn Errors of
Metabolism of HC-UFMG. The measurement of the ChT
activity was performed as previously described by Hollak
and coworkers (1994). Briefly, 5 mL of diluted plasma was
incubated with 200 mL of a solution containing 0.022 mM of
the artificial substrate 4-methylumbelliferyl-b-D-N-N0-N00-
triacetylchitotrioside (Sigma-Aldrich Co., St. Louis, MO,
USA) in citrate-phosphate buffer (0.1/0.2 M) (Sigma-Aldrich
Co., St. Louis, MO, USA), pH 5.2, for 15 min at 37 C. The
reaction was interrupted by adding 2 mL of 0.3 M glycine
buffer (Sigma-Aldrich Co., St. Louis, MO, USA), pH 10.6.
The fluorescent 4-MU was measured with a spectrofluorom-
eter Hitachi F-2500 (Hitachi High-Technologies Corporation,
Tokyo, Japan), excitation (EX) at 366 nm and emission (EM)
at 446 nm. The slit width was 5 nm, both EM and EX. The
coefficient of variation (CV) between duplicates was 5%,
which makes the test highly reproducible (Canudas et al.
2001; Comabella et al. 2009; Vellodi et al. 2005). ChT
activity was expressed in nanomols of hydrolyzed substrate
per hour per mL (nmol/h/mL).
Statistical Analysis
Analyses were performed using the statistical software
package SPSS 14.0. Results are presented as median and
range (minimum and maximum). Four GD type 1 patients
and three healthy controls showed no detectable ChT
activity and therefore were excluded from further statistical
analysis (Canudas et al. 2001). The nonparametric Mann–
Whitney test was used in order to evaluate differences in
ChT activity between GD type 1 patients and controls, and
also among patients and control individuals grouped by
genotype. The same test was used to verify the effect of
gender on enzyme activity. The relations between ChT
activity and age were tested by the Spearman correlation.
Chi-square test was used to evaluate differences in
Table 1 Primers used for analysis of the CHIT1 polymorphisms
Polymorphisms Primers (5’–3’) Fragment Size Annealing temperature Reference
G102S F: ACATAGGCACTTTCACACGTC 380 bp 56 C Lee et al. (2007)
R: AACAGCCTGGAGCAAAGCTC
G354R* F: GAATCTACAGCCACTCACAGG 551 bp 56 C –
R: CAGGTAAGAGAGGAACAAGG
A442V* F: GGGGAGCCTTGGTTGAATCT 423 bp 56 C –
R: TGAGAGCAGAAAGCCTGGATA
* The primers for analysis of the G354R and A442V polymorphisms were based on CHIT1 genomic sequence from NCBI database
(NG_012867.1)
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frequency of dup24 genotype between genders in GD type
1 patients. In all tests, the level of significance was set at
p < 0.05.
Results
Of the 33 GD type 1 patients, 23 (70%), seven (21%), and
three (9%) were, respectively, wild type (wt/wt), heterozy-
gous (wt/dup24), and homozygous (dup24/dup24) mutants
for the allele dup24 (Fig. 1). Among healthy controls, 15
(45.5%), 15 (45.5%), and three (9%) showed, respectively,
wt/wt, wt/dup24, and dup24/dup24 genotypes. The fre-
quency of the wt and dup24 alleles among patients was
0.803 and 0.197, respectively, and 0.682 and 0.318 in the
control group. The genotype distribution was in Hardy-
Weinberg equilibrium.
As expected, plasma ChT activity was 176 times higher
in 29 treated patients with GD type 1 (median: 5092, range:
115–29284 nmol/h/mL) than in control group (median: 29,
range: 7–68 nmol/h/mL; p < 0.0001) (Table 2). Patients
with wt/wt genotype (median: 6011, range: 115–29284
nmol/h/mL) showed ChT activity 194 times higher than
healthy controls with the same genotype (median: 31,
range: 17–68 nmol/h/mL; p < 0.0001). Patients with the
genotype wt/dup24 (median: 2496 nmol/h/mL, range:
652–4417 nmol/h/mL) showed ChT activity 119 times
higher than healthy wt/dup24 controls (median: 21, range:
7–52 nmol/h/mL; p < 0.0001) (Table 2). GD type 1
patients and controls with the genotype dup24/dup24
presented no ChT activity. Considering GD type 1 patients
with different genotypes, the ChT activity was about twice
lower in patients with the genotype wt/dup24 when
compared to patients with the wt/wt genotype ( p < 0.05).
No correlation was observed between ChT activity and
age in both populations ( p > 0.05). No relationship was
noted between gender and ChT activity ( p > 0.05) or
gender and distribution of dup24 genotype ( p > 0.05) in
GD type 1 patients.
Two homozygous (P1 and P2) and one heterozygous
(P3) patients for the dup24 wild type allele showed lower
ChT activity levels than the average reported in their group
(Fig. 1). Consequently, they were screened for three
polymorphisms that have been shown to reduce ChT
enzyme activity. We found that patient P1 (ChT activity of
115 nmol/h/mL) was homozygous for the polymorphism
G102S, which is a guanine to adenine transition at position
304 of the cDNA (c.304G>A). Patient P2 (ChT activity of
206 nmol/h/mL) was heterozygous for the same polymor-
phism. Cloning confirmed the heterozygosity in this
patient. Patient P3 (null ChT activity) presented two
alterations in exon 11. This patient was found to be
heterozygous for the polymorphism G354R, which is a
guanine to adenine transition at position 1060 of the cDNA
(c.1060G>A) and for a 4-base deletion in exon-intron 11
boundary (g.16993_16996delGAGT; rs143439055) (Fig. 2).
This is the first report on this deletion to date.
None of the patients evaluated presented the polymor-
phism A442V, which is a cytosine to thymine transition at
the position 1325 of the cDNA (c.1325C>T).
Discussion
To achieve a better monitoring of GD type 1 patients and
correlate ChT activity with treatment efficacy we measured
the enzyme levels and correlated them with the CHIT1
genotype of each of the 33 GD type 1 patients under
treatment.
Our results showed that the ChT activity was higher in
most GD type 1 patients analyzed than in the healthy
controls, which is in accordance with previous studies
(Hollak et al. 1994; Ries et al. 2006; Wajner et al. 2004,
2007). Wajner and colleagues (2004, 2007) reported that the
ChT activity was around 600-fold greater in untreated GD
patients of Brazilian origin than in healthy individuals. In the
present study, GD type 1 patients also showed an elevation
in the levels of enzyme activity; however, it was only 176
times higher. The divergence may be explained by the fact
that all patients in our study were under treatment, whereas
patients reported by Wajner and colleagues were receiving
no treatment. We observed that ChT activity in GD type 1
patients homozygous wild type was approximately twice
higher than in heterozygous patients. This result is in
accordance with Schoonhoven and co-authors (2007), and
Fig. 1 Levels of ChT activity in 33 GD type 1 patients. Circles
represent the ChT activity in each GD type 1 patient evaluated
conform dup24 genotype. The enzyme activity was undetectable in
patients with dup24/dup24 genotype (n ¼ 3) and in patient P3 and
reduced in patients with wt/dup24 genotype (n ¼ 7). Patients P1, P2,
and P3 are highlighted on the graph
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can be explained by the presence of the null allele dup24,
which does not produce active enzyme (Boot et al. 1998).
The causes for this activity increase are not yet
established. Some studies suggest that in GD type 1 patients
the accumulation of the immunogenic components in macro-
phages, such as ceramide and sphingolipids, causes cellular
activation and consequently ChT secretion, which may
mediate the immune response involved (Ballou et al. 1996;
van Eijk et al. 2005). Increased ChT activity was also
recorded in several other diseases, such as Niemann-Pick
(Brinkman et al. 2005), GM1 gangliosidosis (Malaguarnera
et al. 2003), b-thalassemia (Barone et al. 1999), sarcoidosis
(Boot et al. 2010), malaria (Barone et al. 2003), athero-
sclerosis (Artieda et al. 2003; Boot et al. 1999), and fungal
and bacterial infections (Iyer et al. 2009; Labadaridis et al.
1998). The role of ChT enzyme is unclear, but a possible role
in defense against chitin-containing pathogens and host
immune response has been suggested (Choi et al. 2001;
Di Luca et al. 2007; Di Rosa et al. 2005; Gordon-Thomson
et al. 2009; Malaguarnera et al. 2005; van Eijk et al. 2005).
It is estimated that approximately 6% and 33–35% of the
general population is homozygous and heterozygous for the
mutation dup24, respectively (Boot et al. 1998). In our
study, we found that 9% and 21% of GD type 1 patients
present the genotypes dup24/dup24 and wt/dup24, respec-
tively. Among healthy controls, 9% were dup24/dup24 and
45.5% were wt/dup24. The deviations observed can be
attributed to the not large enough number of evaluated
samples, and also to selection bias, since among GD type 1
patients there were six families, and twelve related
individuals. The Hardy-Weinberg test revealed that the
frequency of dup24 genotypes in GD type 1 patients and
healthy controls is in equilibrium. However, the p value
observed for the group of GD type 1 patients was p ¼ 0.06,
which is very close to the level of significance cut-off. This
may also be due to the number of patients genotyped and/or
selection bias.
Genotyping of polymorphisms in the CHIT1 gene for three
patients (P1, P2, and P3) who presented divergent correlation
between dup24 genotype and ChT activity revealed that
patients P1 and P2 were, respectively, homozygous and
heterozygous for G102S polymorphism. Grace and coworkers
(2007) showed, using 4-MU-chitotrioside as substrate, that
recombinant expressed G102S ChT had only 23% residual
activity in relation to the wild type ChT. On the other hand,
Lee and colleagues (2007) analyzing GD type 1 patients
noted that this polymorphism was not associated with
reduced enzyme activity. Bussink and co-authors (2009)
reported that G102S affects differentially the ChT activity
depending on the substrate used for enzyme measurement:
when the substrate 4-MU-chitotrioside was used, the mutated
ChT containing Ser102 showed reduced catalytic efficiency;
whereas normal catalytic efficiency of the enzyme
containing Ser102 was observed when the substrate 4-MU-
deoxychitobioside (Aguilera et al. 2003) was used. In the
present study, we used the substrate 4-MU-chitotrioside, and
this may explain the low enzyme activity observed.
Furthermore, the mentioned authors reported a considerable
overlap of results and a relatively high frequency of the
G102S allele in different ethnic groups. Thus, we cannot
exclude the possibility that GD type 1 patients that were not
genotyped do not present this polymorphism.
The patient P3 showed more complex changes in CHIT1
gene. Besides presenting the wt/dup24 genotype, this
patient is heterozygous for the G354R polymorphism in
exon 11, which has been previously associated with
reduced ChT activity (Grace et al. 2007; Lee et al. 2007).
Interestingly, this patient presented a 4-base deletion at the
exon-intron 11 boundary (g.16993_16996delGAGT), first
reported in this study. This deletion involves the last two
bases of exon 11 and the first two positions of intron 11,
altering the 5' donor splice-site. A similar genotype was
described by Grace and colleagues (2007), whose patient
with GD type 1 showed three alterations, called “complex
E/I-10 allele”: a G354R polymorphism, a silent base change
(L385L) in exon 11, and a 4-base deletion in intron 11. The
mutation described in the present study changes the 5'










GD type 1 33 100 5092 (115–29284)
wt/wt 23 70 6011 (115–29284)






33 100 29 (7–68)
wt/wt 15 45.5 31 (17–68)




C C CT TA A A A A AACG GPatient P3
Reference Sequence
G G G G G G G
C C CT TA A A A A AACG G G G AG GTG G G G G
Exon 11 Intron 11
Fig. 2 4-base deletion (g.16993_16996delGAGT) at the exon-intron
11 boundary in patient P3. This deletion involves the last two bases of
exon 11 (GA) and the first two positions of intron 11 (GT).
The nomenclature g.16993_16996delGAGT was based on CHIT1
genome sequence from NBCI (NG_012867.1)
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donor splice-site, leading to a splice error which may
underlie the absence of ChT activity observed in patient P3.
This mutation may produce a truncated ChT enzyme, but
future studies will be needed to confirm this hypothesis.
In conclusion, this study characterized the ChT activity
in 33 GD type 1 patients from Minas Gerais state under
ERT and SRT treatment and described a novel mutation in
the CHIT1 gene with important implications for diagnosis
and therapeutic monitoring of patients. We found that ChT
activity cannot be used as biomarker in 18% of GD patients
evaluated, since these patients had null (four patients) or
low (P1 and P2) ChT activity. Such knowledge can improve
the planning of treatment aiming at improving the response
of GD type 1 patients to ERT and SRT.
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